Moffitt Cancer Center
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-855-403-3657), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagra
20th Annual Clinical Breakthrough & Challenges in Hematologic Malignancies
Moffitt Cancer Center
Management of First MM Relapse Debate: Cilta-Cel for All - No
FEATURING
Doris Hansen
- 58 views
- March 10, 2025
- 1
Moffitt Cancer Center
State-of-the-Art: Understanding Precursor States - CHIP and CCUS
FEATURING
Zoey Xie
- 46 views
- March 6, 2025
Moffitt Cancer Center
2025 Updates on Treating Anemia in LR-MDS
FEATURING
Rami Komrokji
- 129 views
- March 6, 2025
Moffitt Cancer Center
Debate: Should MRD Status be Used to Alter Treatment Decisions in High-Risk MDS & AML? Yes
FEATURING
David Sallman
- 24 views
- March 6, 2025
Moffitt Cancer Center
Debate: Should MRD Status be Used to Alter Treatment Decisions in High-Risk MDS & AML? No
FEATURING
Nelli Bejanyan
- 22 views
- March 6, 2025
Moffitt Cancer Center
Management of First MM Relapse Debate: Cilta-Cel for All - Yes
FEATURING
Omar Castaneda Puglianini
- 35 views
- March 6, 2025
- 1
Moffitt Cancer Center
Beyond CAR-T: Management of Post-BCMA CAR-T Relapse in RRMM
FEATURING
Ariel Grajales-Cruz
- 89 views
- March 6, 2025
- 1
Moffitt Cancer Center
How I Treat High-Risk Multiple Myeloma: Interactive Case Discussion
FEATURING
Kenneth Shain
- 117 views
- March 6, 2025
- 2
Moffitt Cancer Center
AQUILA Trial: Daratumumab vs. Active Monitoring in SMM - Perspectives for Practice
FEATURING
Rachid Baz
- 30 views
- March 6, 2025
Moffitt Cancer Center
Summary of Data for Transplant-Ineligible NDMM: Proposed SoC Approach
FEATURING
Rachid Baz
- 168 views
- March 6, 2025
- 2
Moffitt Cancer Center
LR-MDS Updates + Panel Discussion: Focus on Ph3 IMerge Trial
FEATURING
Andrew Kuykendall
- 38 views
- March 6, 2025
Moffitt Cancer Center
Revumenib for KMT2Ar R/R Acute Leukemia - AUGMENT-101 Trial: Impact on Treatment Landscape
FEATURING
Andrew Kuykendall
- 98 views
- March 6, 2025
- 2
